On July 7, the FDA posted a batch of warning letters to websites selling ketamine directly to American consumers for depression and pain. The Center for Drug Evaluation and Research told the operators to stop, citing unapproved and misbranded products. All but one were based in the United States, with the remaining site in the Netherlands.
The letters make the safety case in unusually direct language. Ketamine is not FDA-approved for any psychiatric use at all, and the agency told one recipient that "Ketamine is not FDA-approved for the treatment of any psychiatric disorder."The approved derivative, esketamine, is sold as Spravato, is restricted to certified treatment centers, and carries a boxed warning.
Trade publications counted the letters differently, with some reporting 14 recipients and others 15. That discrepancy is worth noting rather than resolving, and it reflects how the letters were batched and posted rather than any dispute about the underlying action.
What the enforcement does not address is the condition that built the market it is targeting.
Why the Supply Question Sits Underneath the Enforcement
Injectable ketamine has been on national drug shortage lists for years. The disruptions trace back to the early 2020s, when pandemic-era intensive care demand for sedation collided with a rapid expansion of off-label psychiatric use in ketamine clinics. Manufacturing capacity has remained constrained since.
That matters because scarcity in a regulated channel does not eliminate demand. It relocates it. When approved supply is tight and legitimate clinic access is expensive, geographically limited, or backed up, a portion of the people seeking treatment will look for another route. The websites in the July 7 letters were selling into exactly that gap, marketing products as treatments for depression and for acute and chronic pain.
This is a systems question rather than a motive question. Nothing in the enforcement record suggests the agency is doing anything other than what it is supposed to do when unapproved drugs are sold online. The open question is whether letters alone can shrink a market that scarcity and access barriers created, when the approved alternative remains hard to obtain.
What Makes the Gray Market Specifically Dangerous
The FDA's letters set out the mechanism clearly. The agency said unapproved and misbranded ketamine sold over the internet "put US consumers at risk of serious adverse events." In one letter, it warned that unapproved products can contain varying levels of active ingredient or different ingredients altogether.
Injectable products carry the sharpest risk. A non-sterile injectable can seed a bloodstream infection, and the agency specifically flagged the potential for septicemia or sepsis from contaminated samples. There is no lot testing, no sterility assurance and no recall mechanism behind a product shipped from an unregistered seller.
Dosing is the second problem. Ketamine has dissociative and cardiovascular effects that are managed in clinical settings through monitoring, and the agency said it "has identified significant risks associated with unapproved ketamine products," particularly without medical supervision.
There is also a longer-term concern that is easy to miss in a single-transaction framing. Ketamine is a Schedule III controlled substance with real potential for misuse and, at sustained high doses, for bladder and urinary tract damage. Unsupervised escalation is the pathway to that harm.
Who Is Affected and How
Two groups sit on either side of this.
Patients with treatment-resistant depression are the population the online sellers advertise to. Many have cycled through multiple antidepressants without benefit, and for some the evidence for ketamine and esketamine is genuinely meaningful. They are also the group least able to absorb a delay or a denial, because the condition itself erodes the capacity to navigate a difficult access process.
Clinicians in anesthesiology, emergency medicine, and pain management sit on the other side, where injectable ketamine is a workhorse drug and shortages force substitution in procedural sedation and acute pain control.
Cost is the recurring barrier for the psychiatric population. Ketamine infusions at clinics are frequently not covered by insurance and are paid out of pocket, which is a substantial part of why an online seller advertising a lower price finds an audience.
What Patients Should Do
Anyone currently considering ketamine for a mood disorder should have that conversation with a psychiatrist or their primary care clinician rather than with a website. Ask specifically about Spravato, which is FDA-approved for treatment-resistant depression and for depressive symptoms with acute suicidal ideation in adults with major depressive disorder, is administered in a certified setting under observation, and is more likely to have a coverage pathway than a cash-pay infusion.
Anyone who has already obtained ketamine from an online seller should tell a clinician. That disclosure is clinically important and should not be withheld out of embarrassment. Do not stop a prescribed antidepressant to start something bought online, and do not inject a product of unknown origin.
Signs that warrant prompt medical attention after use include fever, redness, swelling or pain at an injection site, confusion that does not resolve, chest pain, and difficulty urinating or blood in the urine.
Anyone experiencing thoughts of suicide should contact the 988 Suicide and Crisis Lifeline by call or text, and emergency care is appropriate for immediate risk.
What Happens Next
The FDA maintains a public list of internet pharmacy warning letters, and further actions in this area are likely given the agency's parallel enforcement against compounded GLP-1 marketing over the past year. Whether the sites in the July 7 batch comply, rebrand or relocate is the near-term thing to watch, since offshore and rapidly renamed storefronts are a known limitation of this enforcement tool.
The supply side has its own timeline. Additional generic entrants into the injectable market would ease the shortage, and shortage status can be checked against the FDA drug shortage database and the ASHP list, which do not always agree.
The confirmed development is a federal enforcement sweep against online ketamine sellers. The people most affected are patients with treatment-resistant depression facing cost and access barriers to the approved options. The most reasonable step is a conversation with a clinician about Spravato and about coverage. The central uncertainty is whether enforcement can outpace a gray market that exists partly because the legitimate supply is thin.
Frequently Asked Questions
What did the FDA do? On July 7, it posted warning letters to websites selling unapproved and misbranded ketamine to U.S. consumers, ordering them to stop. Counts reported in trade press ranged from 14 to 15 recipients.
Is ketamine approved for depression? No. Ketamine is approved as a general anesthetic. The derivative esketamine, sold as Spravato, is approved for treatment-resistant depression and administered in certified settings.
Why is there a shortage? Injectable ketamine supply has been constrained since the early 2020s, driven by pandemic-era intensive care demand and rapid growth in off-label psychiatric use.
What is the risk from online ketamine? Unknown purity and dose, no sterility assurance, and no recall mechanism. FDA warned that contaminated injectable products can cause septicemia or sepsis.
I already bought some. What should I do? Tell a clinician. Do not inject a product of unknown origin, and seek care for fever, injection-site infection, chest pain, persistent confusion or urinary symptoms.
Is compounded ketamine the same thing? No. Compounded preparations from a licensed pharmacy under a prescription are a different legal category from unapproved products sold directly online, though FDA has also scrutinized how compounded ketamine is marketed.
Where can I check shortage status? The FDA drug shortage database and the ASHP shortages list. The two do not always agree, so checking both gives a fuller picture.
